After years of layoffs, cash burn and political attacks, Moderna secured a major win as its melanoma vaccine trial delivered promising results. At its headquarters, Chief Executive Stephane Bancel rallied thousands of employees, declaring the breakthrough a pivotal moment in the company’s decadeslong pursuit of using mRNA to treat cancer. Staffers toasted with sparkling wine, echoing the emotion of the initial pandemic vaccine announcement.

The news sent Moderna’s stock soaring, nearly tripling and adding $44 billion to its market value. This rally provides crucial relief after shares fell more than 90% from their peak amid falling sales and public skepticism. Built alongside partner Merck, the personalized therapy marks a strategic shift toward sustainable blockbuster growth beyond infectious disease vaccines.

Significant hurdles remain. The drug still requires regulatory approval from the U.S. government, which has halted hundreds of millions in mRNA funding. Manufacturing personalized doses will be expensive, and full clinical details are pending. Nobel laureate Dr. Robert Langer stressed that while crossing this milestone is remarkable, long-term durability and wider patient application demand further verification.